Abstract | BACKGROUND: METHODS: Eleven consecutive patients with newly diagnosed olfactory neuroblastoma were treated with etoposide (75 mg/m2), ifosfamide (1000 mg/m2), and cisplatin (20 mg/m2) all administered intravenously on Days 1-5. Cycles were repeated every 21 days. Patients were excluded from analysis if they had previously received surgery or radiotherapy. RESULTS: Nine patients achieved objective responses (objective response rate, 82%; 95% confidence interval, 52-95%), which included 2 complete responses and 7 partial responses. The major side effect was hematologic toxicity, with Grade 3/4 neutropenia observed after the receipt of 37% of all cycles and febrile neutropenia observed after the receipt of 2 cycles. All toxic events were reversible, and no chemotherapy-related deaths were documented. The median survival period was 18 months (range, 3-45 months). CONCLUSIONS:
|
Authors | Dong-Wan Kim, Yo-Han Jo, Jee Hyun Kim, Hong-Gyun Wu, Chae Seo Rhee, Chol Hee Lee, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim |
Journal | Cancer
(Cancer)
Vol. 101
Issue 10
Pg. 2257-60
(Nov 15 2004)
ISSN: 0008-543X [Print] United States |
PMID | 15484215
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | (c) 2004 American Cancer Society |
Chemical References |
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Antineoplastic Agents, Phytogenic
- Etoposide
- Cisplatin
- Ifosfamide
|
Topics |
- Adult
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects)
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cisplatin
(administration & dosage, adverse effects)
- Esthesioneuroblastoma, Olfactory
(drug therapy, mortality, pathology)
- Etoposide
(administration & dosage)
- Female
- Humans
- Ifosfamide
(administration & dosage, adverse effects)
- Immunohistochemistry
- Male
- Middle Aged
- Nasal Cavity
(pathology)
- Neoadjuvant Therapy
- Nose Neoplasms
(drug therapy, mortality, pathology)
- Retrospective Studies
- Survival Analysis
- Treatment Outcome
|